NCT02658357View on ClinicalTrials.gov

Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant

PHASE2CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

August 31, 2017

Study Completion Date

August 31, 2017

Conditions
SchizophreniaSchizo-affective Disorder
Interventions
DRUG

Risperidone Implant

Trial Locations (1)

33021

Segal Institute for Clinical Research 1201 North 37th Avenue, Hollywood

Sponsors
All Listed Sponsors
lead

Braeburn Pharmaceuticals

INDUSTRY

NCT02658357 - Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant | Biotech Hunter | Biotech Hunter